Hajime Terada

Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.

Arsenic trioxide therapy has recently been found to be very effective in relapsed or refractory acute promyelocytic leukemia. It has resulted in complete remission in more than 52% of cases in China and the United States (1, 2). Shen and colleagues (1) have given the most detailed report of adverse events related to arsenic trioxide therapy. Although most of the patients in their study were critically ill, arsenic trioxide was relatively well tolerated. Updated analyses showed that nonlife-threatening cardiac toxicities related to arsenic trioxide occurred in 8 of 47 patients (3). Electrocardiographic abnormalities, such as QRS complex broadening, prolonged QT intervals, ST-segment depression, T-wave flattening, and multifocal ventricular tachycardia, have been reported in acute arsenic poisoning (4-6). Recently, Huang and colleagues (7) found that 1 patient developed complete atrioventricular block during arsenic trioxide therapy and required implantation of a permanent pacemaker. After observing a prolonged QT interval in the first patient with relapsed acute promyelocytic leukemia who received arsenic trioxide in our hospital, we used continuous monitoring to prospectively examine electrocardiograms and echocardiograms and determine the cardiac toxicities of arsenic trioxide in 8 patients with this disease. We observed prolonged QT intervals in all 8 patients and serious arrhythmias in 4 patients. Methods We used arsenic trioxide to treat 8 patients with acute promyelocytic leukemia who had relapse after extensive previous therapy with all-trans retinoic acid and chemotherapy, including anthracycline (Table). Arsenic trioxide was provided by PolaRx Biopharmaceuticals, Inc. (New York, New York). Our protocol, which was the same as that of a phase II study in the United States, was reviewed and approved by the institutional review board of Hamamatsu University School of Medicine in Hamamatsu, Japan. All patients gave written informed consent and were hospitalized while receiving arsenic trioxide (0.15 mg/kg of body weight), which was administered daily by 2-hour infusion for a maximum of 60 days. Treatment was discontinued if patients met conventional criteria for complete remission (cellular bone marrow aspirate with blasts 5%, absolute neutrophil count 1.5 109 cells/L, and platelet count 100 109 cells/L). Patients who achieved complete remission received one additional 25-day course of arsenic trioxide at the same dose between 3 and 6 weeks after induction therapy. Patients were continuously monitored with ambulatory electrocardiography while receiving arsenic trioxide, and standard 12-lead electrocardiography was performed at least once per week. The QT intervals were calculated in the weekly electrocardiograms, were expressed as the mean values in the 12-lead electrocardiograms, and were corrected by heart rates according to the Bazett formula (QTc interval=QT interval/R-R interval) (8). Table. Patient Characteristics and Prolongation of the QTc Interval during Arsenic Trioxide Therapy The funding source had no role in the collection, analysis, or interpretation of the data or in the decision to submit the paper for publication. Results Five patients (63%) achieved complete remission, and 4 patients received the second course of arsenic trioxide as consolidation therapy. Long QTc intervals (>440 ms) had been noted in 4 of 8 patients before arsenic trioxide therapy. Prolonged QT intervals were observed in all patients during induction therapy with arsenic trioxide and in 3 of 4 patients during the second course of therapy after complete remission (Table). The PQ interval and QRS duration were not prolonged in any case. Ventricular premature contractions were seen during 8 of 12 courses of therapy. Four patients developed nonsustained monomorphic ventricular tachycardia ( 3 successive ventricular premature contractions that stopped spontaneously within 30 seconds) and received antiarrhythmic agents (mexiletine HCl and lidocaine HCl). No patients developed sustained ventricular tachycardia or polymorphic ventricular tachycardia. Patient 1 received arsenic trioxide therapy during his second relapse. The QTc interval was prolonged gradually until day 33 and reverted to the pretreatment level after arsenic trioxide was stopped on day 43. The patient had seven successive ventricular premature contractions on day 25 when the QTc interval was 474 milliseconds (Figure). Therefore, mexiletine HCl (150 mg/d) was administered from day 28 to day 148 during arsenic trioxide therapy. The second course of arsenic trioxide with prophylactic mexiletine HCl was started on day 114. Although similar prolonged QT intervals were seen, only isolated ventricular premature contractions, not ventricular tachycardia, were induced. Patient 3 received arsenic trioxide for 46 days as induction therapy during her second relapse. She had five successive ventricular premature contractions on day 5 and three on day 31. She was given amphotericin B and received potassium and calcium supplements because she had low-normal levels of serum potassium and calcium on day 5. The QTc interval was prolonged from 408 to 460 milliseconds until day 50 and decreased to 442 milliseconds on day 87, when the second course was started. The second course again caused a prolonged QT interval. Figure. Electrocardiographic tracing and QT intervals in patient 1 during arsenic trioxide therapy. Patient 6 had two acute myocardial infarctions before developing acute promyelocytic leukemia. He relapsed four times and received large doses of chemotherapy before receiving arsenic trioxide. The ejection fraction was low (0.45) before arsenic trioxide therapy began. The patient had been receiving mexiletine HCl, 300 mg/d, since his second myocardial infarction. On day 38, nonsustained ventricular tachycardia (27 successive beats) was noticed when the QTc interval was prolonged from 443 to 485 milliseconds. Arsenic trioxide was reduced to 0.1 mg/kg per day and was administered intermittently until day 92 with lidocaine HCl or verapamil HCl. However, the patient developed accelerated idioventricular rhythm on day 62 and nonsustained ventricular tachycardia on day 70. He did not achieve complete remission, and arsenic trioxide therapy was discontinued on day 92. Patient 7 had nonsustained ventricular tachycardia before arsenic trioxide therapy in her second relapse, and mexiletine HCl, 150 mg/d, was given prophylactically until day 54. Arsenic trioxide was not effective and was withdrawn on day 40. The QTc interval was prolonged from 448 to 479 milliseconds; however, no serious arrhythmias were induced. Patient 8, who had a second relapse, had four successive ventricular premature contractions on day 23 and day 24 when the QTc interval was 461 milliseconds. Arsenic trioxide was withdrawn on day 23, and mexiletine HCl, 300 mg/d, was given. Thereafter, no ventricular tachycardia developed and arsenic trioxide therapy was restarted on day 26. Complete remission occurred, and arsenic trioxide therapy was stopped on day 41. No patient developed echocardiographic abnormalities (such as contractile dysfunction, cardiac enlargement, or hypertrophy) except the patient with previous myocardial infarctions. Serum electrolyte levels were within normal limits in all patients during the study. Discussion We used continuous monitoring by ambulatory electrocardiography to show prolonged QT intervals in 8 patients receiving arsenic trioxide. Ventricular arrhythmias, including ventricular tachycardia, developed in 5 of 12 courses of therapy and were associated with prolonged QT intervals. Previous reports of cardiographic abnormalities in arsenic trioxide therapy have shown low-flat T-wave, sinus tachycardia, prolonged QT intervals, and atrioventricular blocks, but not ventricular arrhythmias (1, 2, 7). However, multifocal ventricular tachycardia and ventricular fibrillation have been reported in arsenic poisoning (4-6). The tachyarrhythmias in our study were not sustained ventricular tachycardia or torsade de pointes but nonsustained ventricular tachycardia, accelerated idioventricular rhythm, or paroxysmal supraventricular tachycardia. It is unknown why polymorphic ventricular tachycardias and torsade de pointes were not observed. We believe that spatial inhomogeneity (QT dispersion) or abnormal ventricular repolarization might also be related to the arrhythmias. Indeed, in some cases, prolonged QT intervals were accompanied by an increase in the QT dispersion with no change in the QRS duration. It remains unclear why arsenic prolongs the QT interval. The metal is known to affect the peripheral nervous system diffusely (9), and imbalance of the sympathetic nervous system may be involved. Arsenic also causes widespread damage in many organs by combining with sulfhydryl proteins (9). A direct effect of arsenic on the myocardium could also be involved. However, the evidence remains speculative and further study is needed. Because of its remarkable effectiveness, arsenic trioxide will continue to be widely used for relapsed or refractory acute promyelocytic leukemia. Since such patients have been heavily treated with chemotherapeutic agents, including anthracycline and all-trans retinoic acid, cardiac damage is likely to be universal before arsenic trioxide therapy begins. Arsenic trioxide thus might induce arrhythmia. In our study, although the number of patients was small, ventricular arrhythmias were observed, often through careful monitoring. Therefore, we believe that patients taking arsenic trioxide should have frequent electrocardiographic monitoring and, in particular, should be monitored carefully for serious arrhythmias when QT intervals are prolonged. Prophylactic antiarrhythmic drugs that do not prolong the QT interval should be used because previous reports showed an association between fatal ventricular tachycardias and prolonged QT intervals in arsenic intoxication (4-6). Elect

KB-R7943 Block of Ca2+ Influx Via Na+/Ca2+ Exchange Does Not Alter Twitches or Glycoside Inotropy but Prevents Ca2+ Overload in Rat Ventricular Myocytes

BACKGROUND The Na(+)/Ca(2+) exchange (NCX) extrudes Ca(2+) from cardiac myocytes, but it can also mediate Ca(2+) influx, load the sarcoplasmic reticulum with Ca(2+), and trigger Ca(2+) release from the sarcoplasmic reticulum. In ischemia/reperfusion or digitalis toxicity, increased levels of intracellular [Na(+)] ([Na(+)](i)) may raise levels of intracellular [Ca(2+)] ([Ca(2+)](i)) via NCX, leading to cell injury and arrhythmia. METHODS AND RESULTS We used KB-R7943 (KBR) to selectively block Ca(2+) influx via NCX to study the role of NCX-mediated Ca(2+) influx in intact rat ventricular myocytes. Removing extracellular Na(+) caused [Ca(2+)](i) to rise, due to Ca(2+) influx via NCX, and this was blocked by 90% with 5 micromol/L KBR. However, KBR did not alter [Ca(2+)](i) decline due to NCX. Thus, we used 5 micromol/L KBR to selectively block Ca(2+) entry but not efflux via NCX. Under control conditions, 5 micromol/L KBR did not alter steady-state twitches, Ca(2+) transients, Ca(2+) load in the sarcoplasmic reticulum, or rest potentiation, but it did prolong the late low plateau of the rat action potential. When Na(+)/K(+) ATPase was inhibited by strophanthidin, KBR reduced diastolic [Ca(2+)](i) and abolished the spontaneous Ca(2+) oscillations, but it did not prevent inotropy. CONCLUSIONS In rat ventricular myocytes, Ca(2+) influx via NCX is not important for normal excitation-contraction coupling. Furthermore, the inhibition of Ca(2+) efflux alone (as [Na(+)](i) rises) may be sufficient to cause glycoside inotropy. In contrast, Ca(2+) overload and spontaneous activity at high [Na(+)](i) was blocked by KBR, suggesting that net Ca(2+) influx (not merely reduced efflux) via NCX is involved in potentially arrhythmogenic Ca(2+) overload.

Sildenafil for primary and secondary pulmonary hypertension.

Sildenafil is a selective inhibitor of cyclic guanosine monophosphate‐specific phosphodiesterase type 5, an enzyme that is abundant in both lung and penile tissues. Sildenafil is widely used to dilatepenile arteries, suggesting that it may also dilate pulmonary arteries in patients with pulmonary hypertension. However, the long‐term hemodynamic effects and safety of the drug in pulmonary hypertension are not known.

Effects of a selective inhibitor of Na+/Ca2+ exchange, KB-R7943, on reoxygenation-induced injuries in guinea pig papillary muscles.

The effects of a novel agent that is reported to selectively block Ca2+ influx by Na+/Ca2+ exchange (NCX), KB-R7943, on the reoxygenation-induced arrhythmias and the recovery of developed tension after reoxygenation, were investigated in guinea pig papillary muscles. KB-R7943 dose-dependently suppressed the contracture tension during low-sodium (21.9 mM) perfusion (23+/-8% of steady-state developed tension at 10 microM vs. 56+/-11% in control; n = 6, p<0.05), but did not change action potential and contractile parameters. During the reoxygenation period after 60-min substrate-free hypoxia, KB-R7943 (10 microM) significantly decreased the incidence of arrhythmias (44 vs. 100% in control; n = 9, p <0.05) and shortened the duration of arrhythmias (16+/-11 vs. 72+/-14 s; p<0.01). KB-R7943 (10 microM) significantly enhanced the recovery of developed tension after reoxygenation (83+/-4 vs. 69+/-3% in control; p<0.05). We conclude that KB-R7943 (10 microM) selectively inhibits the reverse mode of NCX, and that it attenuates reoxygenation-induced arrhythmic activity and prevents contractile dysfunction in guinea pig papillary muscles. These results suggest that Ca2+ influx by NCX may play a key role in reoxygenation injury.

Post-challenge hyperinsulinaemia rather than hyperglycaemia is associated with the severity of coronary artery disease in patients without a previous diagnosis of diabetes mellitus

Objective: To ascertain the prevalence of abnormal glucose metabolism in patients with coronary artery disease (CAD) but no previous diagnosis of diabetes mellitus (DM) and to examine the relation between the severity of CAD and responses of glucose and insulin to the glucose tolerance test. Methods and results: Abnormalities of glucose metabolism and insulin response were analysed in 144 patients with CAD without a previous diagnosis of DM who underwent both coronary arteriography and 75 g oral glucose tolerance test. The proportions of impaired and diabetic glucose tolerance were very high (39% for impaired and 21% for diabetic glucose tolerance); only 40% had normal glucose tolerance. The parameters of glucose metabolism were not associated with the number of diseased coronary arteries or the presence of previous myocardial infarction (MI). However, the insulin concentration at 60 minutes or 120 minutes after glucose challenge, insulin area, and the ratio of insulin to glucose area were significantly higher in patients with significant coronary stenosis and with previous MI. Fasting glucose concentration and most conventional risk factors did not predict post-challenge hyperinsulinaemia. Conclusion: Patients with CAD without a previous diagnosis of DM had a high prevalence of abnormal glucose tolerance. Post-challenge hyperinsulinaemia was associated with the number of diseased coronary arteries and the presence of previous MI. The insulin response to the glucose challenge test requires further investigation as a potential risk factor for CAD and a potential target for intervention.

QUANTIFICATION OF INTRACELLULAR FREE SODIUM IONS BY USING A NEW FLUORESCENT INDICATOR, SODIUM-BINDING BENZOFURAN ISOPHTHALATE IN GUINEA PIG MYOCYTES

Isolated guinea pig myocytes were loaded with the Na(+)-sensitive fluorescent probe, sodium-binding benzofuran isophthalate (SBFI). The 340/380 nm fluorescence ratios were measured with fluorescence microscopy. The distribution of intracellular Na+ concentration ([Na+]i) was homogenous, and the mean resting [Na+]i was 8.4 +/- 0.5 mM. There was a significant relationship (r = 0.66, p less than 0.001) between elevation of [Na+]i and shortening of longitudinal length of the cells, during the perfusion of 100 microM strophanthidin. It is concluded that this method is suitable for measuring [Na+]i in isolated myocytes.

Importance of Ca2+ influx by Na+/Ca2+ exchange under normal and sodium-loaded conditions in mammalian ventricles

Na+/Ca2+ exchange (NCX) is a major Ca2+ extrusion system in cardiac myocytes, but can also mediate Ca2+ influx and trigger sarcoplasmic reticulum Ca2+ release. Under conditions such as digitalis toxicity or ischemia/reperfusion, increased [Na+]i may lead to a rise in [Ca2+]i through NCX, causing Ca2+ overload and triggered arrhythmias. Here we used an agent which selectively blocks Ca2+ influx by NCX, KB-R7943 (KBR), and assessed twitch contractions and Ca2+ transients in rat and guinea pig ventricular myocytes loaded with indo-1. KBR (5 μM) did not alter control steady-state twitch contractions or Ca2+ transients at 0.5 Hz in rat, but significantly decreased them in guinea pig myocytes. When cells were Na+-loaded by perfusion of strophanthidin (50 μM), the addition of KBR reduced diastolic [Ca2+]i and abolished spontaneous Ca2+ oscillations. In guinea pig papillary muscles exposed to substrate-free hypoxic medium for 60 min, KBR (10 μM applied 10 min before and during reoxygenation) reduced both the incidence and duration of reoxygenation-induced arrhythmias. KBR also enhanced the recovery of developed tension after reoxygenation. It is concluded that (1) the importance of Ca2+ influx via NCX for normal excitation-contraction coupling is species-dependent, and (2) Ca2+ influx via NCX may be critical in causing myocardial Ca2+ overload and triggered activities induced by cardiac glycoside or reoxygenation.

A selective inhibitor of Na+/Ca2+ exchanger, SEA0400, preserves cardiac function and high-energy phosphates against ischemia/reperfusion injury

The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion. Langendorff-perfused rat hearts were exposed to 35 minutes global ischemia and 40 minutes reperfusion. Using 31P nuclear magnetic resonance spectroscopy, cardiac phosphocreatine (PCr), ATP, and pHi were monitored. SEA0400 did not change the basic cardiac function, but improved the recovery of left ventricular developed pressure (LVDP) after reperfusion (27.6 ± 4.9 mm Hg in control, 101.2 ± 19.3 mm Hg in 0.1μM, and 115.5 ± 13.3 mm Hg in 1μM SEA0400, means ± SE, n = 6, P < 0.05). SEA0400 reduced left ventricular end-diastolic pressure and increased coronary flow after reperfusion. SEA0400 improved the recoveries of cardiac phosphocreatine and ATP after reperfusion, but did not affect pHi. There were significant linear correlations between left ventricular developed pressure and cardiac phosphocreatine (r = 0.79, P < 0.05), and left ventricular developed pressure and ATP (r = 0.80, P < 0.05). However, SEA0400 increased the incidence and duration of reperfusion ventricular arrhythmias. SEA0400 added only after reperfusion also improved both the contractile function and energy metabolism. It is concluded that the selective inhibition of NCX may be effective to preserve high-energy phosphates and to improve cardiac function after reperfusion, but may not be able to prevent fatal arrhythmias.

A single cell model of myocardial reperfusion injury: changes in intracellular Na+ and Ca2+ concentrations in guinea pig ventricular myocytes.

To investigate the contribution of the changes in intracellular Na+ and Ca2+ concentrations ([Na+]i and [Ca2+]i) to myocardial reperfusion injury, we made an ischemia/reperfusion model in intact guinea pig myocytes. Myocardial ischemia was simulated by the perfusion of metabolic inhibitors (3.3 mM amobarbital and 5 μM carbonyl cyanide m-chlorophenylhydrazone) with pH 6.6 and reperfusion was achieved by the washout of them with pH 7.4. [Na+]i increased from 7.9 ± 2.0 to 14.0 ± 3.4 mM (means ± S.E., p < 0.01) during 7.5 min of simulated ischemia (SI) and increased further to 18.8 ± 3.0 mM at 7.5 min after reperfusion. [Ca2+]i, expressed as the ratio of fluo 3 fluorescence intensity, increased to 133 ± 8% (p < 0.01) during SI and gradually returned to the control level after reperfusion. Intracellular pH decreased from 7.53 ± 0.04 to 6.31 ± 0.04 (p < 0.01) and recovered quickly after reperfusion. Reperfusion with the acidic solution or the continuous perfusion of hexamethylene amiloride (2 μM) prevented the reperfusion-induced increase in [Na+]i. When the duration of SI was prolonged to 15 min, the cell response after reperfusion varied, 16 of 37 cells kept quiescent, 21 cells showed spontaneous Ca2+ waves, and 4 cells out of these 21 cells became hypercontracted. In quiescent cells, both [Na+]i and [Ca2+]i decreased immediately after reperfusion. In cells with Ca2+ waves, [Na+]i transiently increased further at the early phase of reperfusion, while [Ca+]i declined. In hypercontracted cells, [Na+]i increased as much as in ‘Ca2+ wave’ cells, but [Ca2+]i increased extensively and both ion concentrations continued to increase. Reperfusion with the Ca2+-free solution prevented both the [Ca2+]i increase and morphological change. In the presence of ryanodine (10 μM), the increase in [Ca2+]i after reperfusion was augmented and some cells became hypercontracted. We concluded that (1) Na+/H+ exchange is active both during SI and reperfusion, resulting in the additional [Na+]i elevation on reperfusion, (2) the [Na+]i level after reperfusion and the following Ca2+ influx via Na+/Ca2+ exchange are crucial for reperfusion cell injury, and (3) the Ca2+ buffering capacity of sarcoplasmic reticulum would also contribute to the Ca2+ regulation and cell injury after reperfusion.

Heterogeneity and underlying mechanism for inotropic action of endothelin-1 in rat ventricular myocytes

To clarify the mechanisms underlying the positive inotropic action of endothelin‐1 (ET‐1), we investigated the effect of ET‐1 on twitch cell shortening and the Ca2+ transient in rat isolated ventricular myocytes loaded with a fluorescent Ca2+ indicator indo‐1. There was a cell‐to‐cell heterogeneity in response to ET‐1. ET‐1 (100 nm) increased twitch cell shortening in only 6 of 14 cells (44 %) and the increase in twitch cell shortening was always accompanied by an increase in the amplitude of the Ca2+ transient. The ETA‐ and ETB‐receptors antagonist TAK‐044 (100 nm) almost reversed both the ET‐1‐induced increases in twitch cell shortening and in the Ca2+ transient. In the ET‐1 non‐responding cells, the amplitude of the Ca2+ transient never increased. Intracellular pH slightly increased (∼0.08 unit) after 30 min perfusion of ET‐1 in rat ventricular myocytes. However, ET‐1 did not change the myofilament responsiveness to Ca2+, which was assessed by (1) the relationship between the Ca2+ transient amplitude and twitch cell shortening, and by (2) the Ca2+ transient‐cell shortening phase plane diagram during negative staircase. We concluded that there was a cell‐to‐cell heterogeneity in the positive inotropic effect of ET‐1, and that the ET‐receptor‐mediated positive inotropic effect was mainly due to an increase in the Ca2+ transient amplitude rather than to an increase in myofilament responsiveness to Ca2+.